The association of deamidation of Bcl-xL and translocation of Bax to the mitochondria through activation of JNK in the induction of apoptosis by treatment with GSH-conjugated DXR

International Journal of Oncology

Volumn 33, Issue 2, 2008, Pages 389-395

  Asakura, Tadashi ^a   Maeda, Kazuhiro ^a   Omi, Hiroko ^a   Matsudaira, Hiroshi ^a   Ohkawa, Kiyoshi ^a  

^a JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Apoptosis; Bax; Bcl xL deamidation; GSH conjugated DXR; JNK

Indexed keywords

ANTHRA[1,9 CD]PYRAZOL 6(2H) ONE; ARGININE; ASPARTIC ACID; CASPASE 3; CYTOCHROME C; DOXORUBICIN; GLUTATHIONE; PROTEIN BAX; PROTEIN BCL XL; STRESS ACTIVATED PROTEIN KINASE;

AMINO ACID SUBSTITUTION; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CELL TRANSPORT; CONCENTRATION RESPONSE; CONTROLLED STUDY; DEAMINATION; DRUG MECHANISM; DRUG SENSITIVITY; ENZYME ACTIVATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; TRANSPORT KINETICS;

APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; BLOTTING, WESTERN; CASPASE 3; CELL LINE, TUMOR; DOXORUBICIN; ENZYME ACTIVATION; GLUTATHIONE; HUMANS; MAP KINASE KINASE 4; MITOCHONDRIA; PROTEIN TRANSPORT;

EID: 48749107996     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000020     Document Type: Article

References (62)

1. Tsujimoto Y and Shimizu S: Bcl-2 family: life-or-death switch. FEBS Lett 466: 6-10, 2000.
2. Martinou J-C and Green DR: Breaking the mitochondrial barrier. Nat Rev 2: 63-67, 2001.
3. Li P, Nijhawan D, Budihardjo I, Srinivasula SM, Ahmad M, Alnemri ES and Wang X: Cytochrome c and dATP-dependent formation of Apaf-1/caspase-9 complex initiates an apoptotic protease cascade. Cell 91: 479-489, 1997.
4. Zou H, Henzel WJ, Liu X, Lutschg A and Wang X: Apaf-1, a human protein homologous to C. elegans CED-4, participates in cytochrome c-dependent activation of caspase-3. Cell 90: 405-413, 1997.
5. Adams JM and Cory S: The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326, 1998.
6. Asakura T and Ohkawa K: Chemotherapeutic agent which induced mitochondrial apoptosis. Curr Cancer Drug Targets 4: 570-583, 2004.
7. Antonsson B, Montessuit S, Lauper S, Eskes R and Martinou JC: Bax oligomerization is required for channel-forming activity in liposomes and to trigger cytochrome c release from mitochondria. Biochem J 345: 271-278, 2000.
8. Antonsson B, Montessuit S, Sanchez B and Martinou JC: Bax is present as a high molecular weight oligomer/complex in the mitochondrial membrane of apoptotic cells. J Biol Chem 276: 11615-11623, 2001.
9. Wei MC, Zong WX, Cheng EH, Lindsten T, Panoutsakopoulou V, Ross AJ, Roth KA, MacGregor GR, Thompson CB and Korsmeyer SJ: Proapoptotic BAX and BAK: a requisite gateway to mitochondrial dysfunction and death. Science 292: 727-730, 2001.
10. Puthalakath H and Strasser A: Keeping killers on a tight leash: transcriptional and post-translational control of the pro-apoptotic activity of BH3-only proteins. Cell Death Differ 9: 505-512, 2002.
11. Li H, Zhu H, Xu C and Yuan J: Cleavage of BID by caspase 8 mediates the mitochondrial damage in the Fas pathway of apoptosis. Cell 94: 491-501, 1998.
12. Luo X, Budihardjo I, Zou H, Slaughter C and Wang X: Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors. Cell 94: 481-490, 1998.
13. 2+-induced apoptosis through calcineurin dephosphorylation of BAD. Science 284: 339-343, 1999.
14. Puthalakath H, Huang DC, O'Reilly LA, King SM and Strasser A: The proapoptotic activity of the Bcl-2 family member Bim is regulated by interaction with the dynein motor complex. Mol Cell 3: 287-296, 1999.
15. Puthalakath H, Villunger A, O'Reilly LA, Beaumont JG, Coultas L, Cheney RE, Huang DC and Strasser A: Bmf: a proapoptotic BH3-only protein regulated by interaction with the myosin V actin motor complex, activated by anoikis. Science 293: 1829-1832, 2001.
16. Hsu YT, Wolter KG and Youle RJ: Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Natl Acad Sci USA 94: 3668-3672, 1997.
17. Wolter KG, Hsu YT, Smith CL, Nechushtan A, Xi XG and Youle RJ: Movement of Bax from the cytosol to mitochondria during apoptosis. J Cell Biol 139: 1281-1292, 1997.
18. Goping IS, Gross A, Lavoie JN, Nguyen M, Jemmerson R, Roth K, Korsmeyer SJ and Shore GC: Regulated targeting of BAX to mitochondria. J Cell Biol 143: 207-215, 1998.
19. Gross A, Jockel J, Wei MC and Korsmeyer SJ: Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 17: 3878-3885, 1998.
20. Nomura M, Shimizu S, Ito T, Narita M, Matsuda H and Tsujimoto Y: Apoptotic cytosol facilitates Bax translocation to mitochondria that involves cytosolic factor regulated by Bcl-2. Cancer Res 59: 5542-5548, 1999.
21. Nechushtan A, Smith CL, Hsu YT and Youle RJ: Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 18: 2330-2341, 1999.
22. Khaled AR, Kim K, Hofmeister R, Muegge K and Durum SK: Withdrawal of IL-7 induces Bax translocation from cytosol to mitochondria through a rise in intracellular pH. Proc Natl Acad Sci USA 96: 14476-14481, 1999.
23. Tsuruta F, Sunayama J, Mori Y, Hattori S, Shimizu S, Tsujimoto Y, Yoshioka K, Masuyama N and Gotoh Y: JNK promotes Bax translocation to mitochondria through phosphorylation of 14-3-3 proteins. EMBO J 23: 1889-1899, 2004.
24. Haldar S, Jena N and Croce CM: Inactivation of Bcl-2 by phosphorylation. Proc Natl Acad Sci USA 92: 4507-4511, 1995.
25. Blagosklonny MV, Giannakakou P, El-Deiry WS, Kingston DGI, Higgs PI, Neckers L and Fojo T: Raf-1/bcl-2 phosphorylation: a step from microtubule damage to cell death. Cancer Res 57: 130-135, 1997.
26. Fojo T and Blagosklonny MV: Molecular effects of paclitaxel: myths and reality (a critical review). Int J Cancer 83: 151-156, 1997.
27. Ling YR, Tornos C and Perez-Soler R: Phosphorylation of Bcl-2 is a marker of M phase events and not a determinant of apoptosis. J Biol Chem 273: 18984-18991, 1998.
28. Scatena CD, Stewart ZA, Mays D, Tang LJ, Keefer CJ, Leach SD and Pietenpol JA: Mitotic phosphorylation of Bcl-2 during normal cell cycle progression and Taxol-induced growth arrest. J Biol Chem 273: 30777-30784, 1998.
29. Fan M, Goodwin M, Vu T, Brantley-Finley C, Gaarde WA and Chambers TC: Vinblastine-induced phosphorylation of Bcl-2 and Bcl-xL is mediated by JNK and occurs in parallel with inactivation of the Raf-1/MEK/ERK cascade. J Biol Chem 275: 29980-29985, 2000.
30. Kharbanda S, Saxena S, Yoshida K, Pandey P, Kaneki M, Wang Q, Chengi K, Chen Y-N, Campbell A, Sudhai T, Yuan Z-M, Narula J, Weichselbaum R, Nalin C and Kufe D: Translocation of SAPK/JNK to mitochondria and interaction with Bcl-xL in response to DNA damage. J Biol Chem 275: 322-327, 2000.
31. Haldar S, Chintapalli J and Croce CM: Taxol induces bcl-2 phosphorylation and death of prostate cancer cells. Cancer Res 56: 1253-1255, 1996.
32. Takehara T, Liu X, Fujimoto J, Friedman SL and Takahashi T: Expression and role of Bcl-xL in human hepatocellular carcinomas. Hepatology 34: 55-61, 2001.
33. Takehara T and Takahashi H: Suppression of Bcl-xL deamidation in human hepatocellular carcinomas. Cancer Res 63: 3054-3057, 2003.
34. Deverman BE, Cook BL, Manson SR, Niederhoff RA, Langer EM, Rosova' I, Kulans LA, Fu X, Weinberg JS, Heinecke JW, Roth KA and Weintraub SJ: Bcl-xL deamidation is a critical switch in the regulation of the response to DNA damage. Cell 111: 51-62, 2002.
35. David RJ: Signal transduction by the JNK group of MAP kinases. Cell 103: 239-252, 2000.
36. Ichijo H: From receptors to stress-activated MAP kinases. Oncogene 18: 6087-6093, 1999.
37. Ip YT and Davis RJ: Signal transduction by the c-Jun N-terminal kinase (JNK) from inflammation to development. Curr Opin Cell Biol 10: 205-219, 1998.
38. Weston CR and Davis RJ: The JNK signal transduction pathway. Curr Opin Genet Dev 12: 14-21, 2002.
39. 2-induced cell death via coordinated regulation of stress kinases. Cancer Res 60: 4053-4057, 2000.
40. Chen YR, Wang X, Templeton D, Davis RJ and Tan TH: The role of c-Jun N-terminal kinase (JNK) in apoptosis induced by ultraviolet C and gamma radiation. Duration of JNK activation may determine cell death and proliferation. J Biol Chem 271: 31929-31936, 1996.
41. Guo YL, Baysal K, Kang B, Yang LJ and Williamson JR: Correlation between sustained c-Jun N-terminal protein kinase activation and apoptosis induced by tumor necrosis factor-α in rat mesangial cells. J Biol Chem 273: 4027-4034, 1998.
42. Javelaud D and Besançon F: NF-κB activation results in rapid inactivation of JNK in TNFα-treated Ewing sarcoma cells: a mechanism for the anti-apoptotic effect of NF-κB. Oncogene 20: 4365-4372, 2001.
43. Sanchez-Perez I, Murguia JR and Perona R: Cisplatin induces a persistent activation of JNK that is related to cell death. Oncogene 16: 533-540, 1998.
44. Xia Z, Dickens M, Raingeaud J, Davis RJ and Greenberg ME: Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270: 1326-1331, 1995.
45. Adler V, Yin Z, Fuchs SY, Benezra M, Rosario L, Tew KD, Pincus Mr, Sardana M, Henderson CJ, Wolf CR, Davis RJ and Ronai Z: Regulation of JNK signaling by GSTp. EMBO J 18: 1321-1334, 1999.
46. Wang T, Arifoglu P, Ronai Z and Tew KD: Glutathione S-transferase P1-1 (GSTP1-1) inhibits c-Jun N-terminal kinase (JNK1) signaling through interaction with the C terminus. J Biol Chem 276: 20999-21003, 2001.
47. Adler V and Pincus MR: Effector peptides from glutathione-S-transferase-pi affect the activation of jun by jun-N-terminal kinase. Ann Clin Lab Sci 34: 35-46, 2004.
48. Chie L, Adler V, Friedman FK, Chung D and Pincus MR: An effector peptide from glutathione-S-transferase-pi strongly and selectively blocks mitotic signaling by oncogenic ras-p21. Protein J 23: 235-238, 2004.
49. Asakura T, Sasagawa A, Takeuchi H, Shibata S, Marushima H, Mamori S and Ohkawa K: Conformational change in the active center region of GST P1-1, due to binding of a synthetic conjugate of DXR with GSH, enhanced JNK-mediated apoptosis. Apoptosis 12: 1269-1280, 2007.
50. Batist G, Tulpule A, Sinha BK, Katki AG, Meyers CE and Cowan KH: Overexpression of a novel anionic glutathione transferase in multidrug resistant human breast cancer cells. J Biol Chem 261: 15544-15549, 1986.
51. Ramachandran C, Yuan ZK, Huang XL and Krishan A: Doxorubicin resistance in human melanoma cells: MDR-1 and glutathione S-transferase π gene expression. Biochem Pharmacol 45: 743-751, 1993.
52. Cowan KH, Batist G, Tulpule A, Sinha BK and Meyers CE: Similar biochemical changes associated with multidrug resistance in human breast cancer cells and carcinogen-induced resistance to xenobiotics in rats. Proc Natl Acad Sci USA 83: 9328-9332, 1986.
53. Ban N, Takahashi Y, Takayama T, Kura T, Kakahira T, Sakamaki S and Niitsu Y: Transfection of glutathione S-transferase (GST)-π antisense complementary DNA increases the sensitivity of a colon cancer cell line to adriamycin, cisplatin, melphalan, and etoposide. Cancer Res 56: 3577-3582, 1996.
54. Wilce MCJ and Parker MW: Structure and function of glutathione S-transferases. Biochim Biophys Acta 1205: 1-18, 1994.
55. Takahashi N, Asakura T and Ohkawa K: Pharmacokinetic analysis of protein-conjugated doxorubicin (DXR) and its degraded adducts in DXR-sensitive and -resistant rat hepatoma cells. Anticancer Drugs 7: 687-696, 1996.
56. Asakura T, Takahashi N, Takada K, Inoue T and Ohkawa K: Drug conjugate of doxorubicin with glutathione is a potent reverser of multidrug resistance in rat hepatoma cells. Anticancer Drugs 8: 199-203, 1997.
57. Asakura T, Sawai T, Hashidume Y, Ohkawa Y, Yokoyama S and Ohkawa K: Caspase-3 activation during doxorubicin conjugated with glutathione-mediated apoptosis. Br J Cancer 80: 711-715, 1999.
58. Asakura T, Ohkawa K, Takahashi N, Takada K, Inoue T and Yokoyama S: Glutathione-doxorubicin conjugate expresses potent cytotoxicity by a suppression of glutathione S-transferase activity: comparison between doxorubicin-sensitive and -resistant rat hepatoma cells. Br J Cancer 76: 1333-1337, 1997.
59. Asakura T, Hashizume Y, Tashiro K, Searashi Y, Ohkawa K, Nishihira J, Sakai M and Shibasaki T: Suppression of GST-P by treatment with glutathione-doxorubicin conjugate induces potent apoptosis in rat hepatoma cells. Int J Cancer 94: 171-177, 2001.
60. Ohkawa K, Hatano T, Tsukada Y and Matsuda M: Chemotherapeutic efficacy of the protein-doxorubicin conjugates on multidrug resistant rat hepatoma cell line in vitro. Br J Cancer 67: 274-278, 1993.
61. Ohkawa K, Hatano T, Yamada K, Joh K, Takada K, Tsukada Y and Matsuda M: Bovine serum albumin-doxorubicin conjugate overcomes multidrug resistance in a rat hepatoma. Cancer Res 53: 4238-4242, 1993.
62. Nicholson DW, Ali A, Thornbeny NA, Vaillancourt JP, Ding CK, Gallant M, Gareau Y, Griffin PR, Labelle M, Lazebnik YA, Munday NA, Raju SM, Smulson ME, Yamin T-T, Yu VL and Miller DK: Identification and inhibition of the ICE/CED-3 protease necessary for mammalian apoptosis. Nature 376: 37-43, 1995.